Effect of substituents on microsomal reduction of benzo(c)fluorene N-oxides

Chemico-Biological Interactions

Volumn 126, Issue 3, 2000, Pages 185-200

  Skálová, Lenka ^a   Nobilis, Milan ^b   Szotáková, Barbora ^a   Wsól, Vladimír ^a   Kubíček, Vladimír ^a   Baliharová, Vendula ^a   Kvasničková, Eva ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b Inst of Exp Biopharmaceutics   (Czech Republic)

Author keywords

Bioreductive agents; Cytochromes P450; Cytostatics; Microsomal reductases; N oxides

Indexed keywords

ANTINEOPLASTIC AGENT; BENFLURON; BENFLURON N OXIDE; CYTOCHROME P450; CYTOSTATIC AGENT; MICROSOME ENZYME; OXIDOREDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; LIVER HOMOGENATE; MALE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; RAT;

AEROBIOSIS; ANAEROBIOSIS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; CYTOCHROME P-450 ENZYME SYSTEM; FLUORENES; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; RATS; RATS, WISTAR;

EID: 17744414542     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(00)00164-2     Document Type: Article

References (33)

1. Patterson L.H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev. 12(2):1993;119-134.
2. Tercel M., Wilson W.R., Denny W.A. Hypoxia-selestive antitumor agents. 11. Chlorambucil N-oxide: a reappraisal of its synthesis, stability, and selective toxicity for hypoxic cells. J. Med. Chem. 38(7):1995;1247-1252.
3. Elwell J.H., Siim B.G., Evans J.W., Brown J.M. Adaptation of human tumor cells to tirapazamine under aerobic conditions. Biochem. Pharmacol. 54:1997;249-257.
4. Graham M.A., Senan S., Robin H. Jr, Eckhardt N., Lendrem D., Hincks J., Greenslade D., Rampling R., Kaye S.B., von Roemeling R., Workman P. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice nad humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother. Pharmacol. 40:1997;1-10.
5. Senan S., Rampling R., Graham M.A., Wilson P., Robin H. Jr, Eckardt N., Lawson N., McDonald A., von Roemeling R., Workman P., Kaye S.B. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin. Cancer Res. 3:1997;31-38.
6. Monge A., Palop J.A., Lépez de Ceráin A., Senador V., Martínez-Crespo F.J., Sain Y., Narro S., Garcia E., de Miguel C., González M. et al. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. J. Med. Chem. 38:1995;1786-1792.
7. Wilson W.R., Van Zijl P., Denny W.A. Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;693-696.
8. Takekawa K., Sugihara K., Kitamura S., Tatsumi K. Nonezymatic reduction of brucine N-oxide by the heme group of cytochrome P450. Biochem. Mol. Biol. Int. 42:1997;977-981.
9. Testa B. Reduction catalyzed by cytochrome P450 and other oxidoreductases. Testa B., Caldwell J. The Metabolism of Drugs and other Xenobiotics, Biochemistry of Redox Reactions. 1995;398-447 Academic Press, London.
10. Kitamura S., Tatsumi K. Menadione-dependent reduction of tertiary amine N-oxide by rat liver cytosol. Biochem. Mol. Biol. Int. 42:1997;271-276.
11. Barham H.M., Stratford I.J. Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase. Biochem. Pharmacol. 51:1996;829-837.
12. Riley R.J., Workman P. Enzymology of the reduction of the potent enzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from walker 256 rat tumour cells. Biochem. Pharmacol. 43(2):1992;167-174.
13. Fitzsimmons S.A., Lewis A.D., Riley R.J., Workman P. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN59075, SR4233) to a DNA-damaging species a direct role for NADPH: cytochrome P450 oxidoreductase. Carcinogenesis. 15(8):1994;1503-1510.
14. Walton M.I., Wolf C.R., Workman P. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem. Pharmacol. 44(2):1992;251-259.
15. Goeptar R.A., Scheerens H., Vermeulen N.P.E. Oxygen and xenobiotic reductase activities of cytochrome P450. Crit. Rev. Toxicol. 25(1):1995;25-65.
16. Soucek J., Stöckbauer P., Melka M., Koubek K., Chudomel V., Krepelka J. Derivatives of benzo(c)fluorene. XXIV. Cytostatic effect of benfluron on human leukemic cells in vitro. Neoplasma. 34(1):1987;45-54.
17. Poucková P., Zadinová M., Krepelka J., Grimová J., Hloušková D. The effect of benflurone (VUFB) on the growth of human rectal carcinoma xenotransplanted into athymic nu/nu mice. Cas. Lek. Cesk. 126(24):1987;751-753.
18. Miko M., Krepelka J., Melka J. Primary screening and inhibition of macromolecular biosynthesis in Ehrlich ascites cells by benzo(c)fluorene derivatives. Drug Metabol. Drug Interact. 9(1):1991;1-22.
19. Miko M., Krepelk J., Melka J. Effects of benfluron and its two metabolites on respiratory processes in P388 murine leukemia and Ehrlich ascites cells. Biochem. Pharmacol. (Suppl.). 42:1991;214-216.
20. Miko M., Krepelka J., Melka M., Vajdová D. Effect of benfluron metabolites on ATP level in tumor cells. Neoplasma. 36(4):1989;411-417.
21. Skálová L., Nobilis M., Szotáková B., Trejtnar F., Kvasnicková E. In vitro and in vivo biotransformation of benflurone N-oxide, a biologically active metabolite of a potential cytostatic. Exp. Toxicol. Pathol. (II). 48:1996;366-370.
22. Skálová L., Nobilis M., Szotáková B., Wsól V., Kvasnicková E. Induction and inhibition of cytochrome P450-catalysed reduction of biologically active benfluron N-oxide. Drug Metab. Interact. 14(4):1998;221-233.
23. Skálová L., Ulrichová L., Szotáková B., Wsól V., Nobilis M., Kvasnicková E. In vitro reduction of tertiary amines N-oxides. Chem. Pap. 52:1998;567.
24. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin C phenol reagent. J. Biol. Chem. 193:1951;165-275.
25. Omura T., Sato R. The carbon-monoxide-binding pigment of liver microsomes. II. Solubilization, purification, properties. J. Biol. Chem. 239:1964;2379-2385.
26. Nobilis M., Anzenbacher P., Pastera J., Svoboda Z., Hrubý K., Kvetina J., Ubik K., Trejtnar F. Study of biotransformation of a potential benzo[c]fluorene antineoplastic using HPLC with high-speed-scanning UV detection. J. Chromatogr. B. 681:1996;143-151.
27. Riley R.J., Hemingway S.A., Graham M.A., Workman P. Initial characterisation of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine), SR 4233, WIN 59075. Biochem. Pharmacol. 45(5):1993;1065-1077.
28. Wislocki P.G., Miwa G.T., Lu A.Y.H. Reactions catalysed by cytochrome P450 system. Jakoby W.B. Enzymatic Basis of Detoxication. 1980;Academic Press, London.
29. Seto Y., Guengerich F.P. Partitioning between N-dealkylation and N-oxygenation in the oxidation of N,N-dialkylarylamines catalysed by cytochrome P450. J. Biol. Chem. 268:1993;9986-9997.
30. Kvasnicková E., Nobilis M., Hais I.M. Chromatographic characterisation of in vitro metabolites of 5[2-(N,N-dimethylamino)ethoxy]-7-oxo-7H-benzo(c)fluorene. J. Chromatogr. 295:1984;201-209.
31. M. Nobilis, E. Kvasničková, A. Šroler, I.M. Hais, Elimination of benflurone and its metabolites in the faeces and urine of rats, Drug Metab. Drug Interact. 9 (3-4) (1991) 225-240.
32. Robertson I.G., Bland T.J., Palmer B.D. Effect of substituents on the metabolism of nitracrine in rat. Xenobiotica. 26:1996;559-569.
33. Lee H.H., Wilson W.R., Ferry D.M., van Zijl P., Pullen S.M., Denny W.A. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. J. Med. Chem. 39:1996;2508-2517.